Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
- PMID: 17234747
- DOI: 10.1158/0008-5472.CAN-06-2871
Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions
Abstract
Oncolytic viruses that can destroy cancer cells have been engineered in a variety of ways with the aim of improving their selectivity and efficacy. Here, we review data from clinical investigations of these virotherapeutic agents, specifically those that have shown systemic efficacy: vaccinia, measles, mumps, viruses, Newcastle disease virus, and reovirus. Further directions for optimizing i.v. delivery and efficacy are discussed.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
